# South Korea Gene Therapy Market > South Korea Gene Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders), By Technology (Viral Vectors, CRISPR, Gene Editing, RNA Therapy, Non-Viral Methods), By Applications (Research, Clinical, Commercial) and By Route of Administration (Intravenous, Intramuscular, Intradermal, Intrathecal, Oral) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 19.04% - **2024:** $ 122.4 Million - **2035:** $ 832.7 Million - **Key Players:** Novartis (CH), Gilead Sciences (US), Spark Therapeutics (US), Bluebird Bio (US), Bristol-Myers Squibb (US), Regeneron Pharmaceuticals (US), Sangamo Therapeutics (US), Amgen (US), Roche (CH) **Report ID:** MRFR/Pharma/51498-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-gene-therapy-market-53259 --- ## Market Summary ## **South Korea Gene Therapy Market Overview** As per MRFR analysis, the South Korea Gene Therapy Market Size was estimated at 129 (USD Million) in 2024.The South Korea Gene Therapy Market Industry is expected to grow from 145.4(USD Million) in 2025 to 612 (USD Million) by 2035. The South Korea Gene Therapy Market CAGR (growth rate) is expected to be around 13.958% during the forecast period (2025 - 2035) **Key South Korea Gene Therapy Market Trends Highlighted** The South Korea gene therapy market is witnessing significant growth driven by several key market drivers. One of the primary factors is the country's robust focus on biotechnology and medical research, which has led to substantial investments in innovative treatments. The South Korean government has launched initiatives to promote the development and commercialization of gene therapies, aiming to enhance healthcare outcomes while establishing the region as a leader in biopharmaceutical technology.  Moreover, the rising prevalence of genetic disorders and chronic diseases is increasing the demand for advanced therapeutic options, highlighting the urgency for effective gene therapies.There are numerous opportunities to be explored in the South Korea gene therapy market. The government’s support for local biotech companies through funding programs and incentives encourages collaboration between research institutions and private entities. This collaboration is fostering an environment where new treatment modalities can be rapidly developed and brought to market.  Additionally, as regulatory frameworks are evolving to be more accommodating for gene therapy approvals, this opens up avenues for novel therapies to reach patients quicker. Trends in recent times show a marked increase in clinical trials focusing on rare diseases and inherited genetic disorders within South Korea, propelled by advancements in precision medicine.The presence of leading research institutions and universities in the country enhances the innovation landscape, making it an attractive destination for international partnerships.  Furthermore, advancement in technologies such as CRISPR and viral vector development are leading to breakthroughs that could change treatment paradigms. The integration of artificial intelligence in gene therapy research is also becoming a focal point, helping to streamline processes and improve outcomes, indicating a future where personalized medicine is within reach for many more patients in South Korea. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South Korea Gene Therapy Market Drivers** **Increasing Investment in Research and Development** The South Korea Gene Therapy Market Industry is experiencing a surge in investment towards Research and Development (R&D), driven by both governmental initiatives and private sector funding. The South Korean government has earmarked significant financial resources for biopharmaceutical innovations, including gene therapy, recognizing its potential to provide advanced medical solutions for various diseases. For instance, the Ministry of Health and Welfare has launched initiatives aimed at enhancing healthcare technologies which designate substantial funds that could account for a yearly increase of 15% in R&D spending specific to gene therapy. This proactive approach showcases the commitment of both public and private organizations, such as Samsung Biologics and Hanmi Pharmaceutical, who have intensified their efforts in developing novel gene-based therapies. Additionally, the increasing number of clinical trials in the region, supported by the Korea National Enterprise for Clinical Trials, emphasizes the flourishing environment for innovation, leading to a projected growth in the South Korea Gene Therapy Market Industry as advanced treatments become available. **Rising Incidence of Genetic Disorders** The increase in the incidence of genetic disorders in South Korea is a significant driver impacting the South Korea Gene Therapy Market Industry. With a reported rise of approximately 20% in genetic disorders over the past decade, including conditions such as hemophilia and cystic fibrosis, the demand for effective gene therapy solutions is paramount. The Korea Centers for Disease Control and Prevention has documented these figures, highlighting the necessity for innovative therapies that can address these complex health issues. With the increase in the average age of the population and the prevalence of certain genetic conditions, organizations like LG Chem and Green Cross Laboratory are more focused on developing individual gene therapies, which in turn is driving market growth due to these healthcare needs. This is likely to accelerate the regional incorporation and introduction of gene therapies. **Supportive Regulatory Framework** The supportive regulatory framework for gene therapies in South Korea significantly contributes to the growth of the South Korea Gene Therapy Market Industry. The South Korean Ministry of Food and Drug Safety (MFDS) has implemented expedited approval processes for innovative therapies, ensuring that new gene treatments reach the market more rapidly. This framework includes provisions for conditional approvals and priority reviews for therapies that address unmet medical needs. For example, the recent approval of a gene therapy for adenosine deaminase deficiency marked a pivotal moment in the adoption of such technologies, illustrating the government's commitment to fostering a pro-innovation environment. Moreover, the MFDS has been encouraging collaborations between domestic biotech firms and international companies, which not only enhances knowledge transfer but also accelerates the development of new options within the market. **Growing Partnership Trends** The trend of growing partnerships and collaborations between biotechnology companies and research institutions is a critical driver influencing the South Korea Gene Therapy Market Industry. Notable collaborations between domestic firms like SK Biopharmaceuticals and international biotechnology companies have paved the way for significant advancements in gene therapy research and development. The collaborative agreements often aim to leverage combined expertise to expedite clinical trials and improve therapeutic outcomes. Furthermore, these partnerships facilitate access to additional funding sources and cutting-edge technologies, positioning South Korea as a hub for gene therapy innovation. The presence of esteemed academic institutions such as Seoul National University, which actively engages in gene therapy research, contributes to a robust ecosystem conducive to collaboration and knowledge sharing, thus propelling the market's growth trajectory. **South Korea Gene Therapy Market Segment Insights** **Gene Therapy Market Therapeutic Area Insights** The South Korea Gene Therapy Market, particularly within the Therapeutic Area segment, showcases a rapidly evolving landscape driven by advancements in biomedicine and technological innovations. With a growing focus on precision medicine, gene therapy presents a promising avenue for treatment within various therapeutic applications, primarily in Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, and Neurological Disorders.  Oncology occupies a significant space in this market due to the increasing incidence of various cancers, pushing continuous demand for targeted therapies that can effectively address specific genetic mutations associated with tumors. Genetic Disorders also represent a crucial area, as gene therapy holds the potential to rectify hereditary conditions by correcting genetic defects at their source, greatly improving patient quality of life. Infectious Diseases continue to gain attention as researchers explore gene therapy's capabilities in developing vaccines and treatments, particularly in response to emerging viral outbreaks. Similarly, Cardiovascular Diseases are increasingly seen as a major target due to the prevalence of conditions linked to genetic predispositions, thereby creating opportunities for innovative therapeutic methods aimed at repairing or replacing damaged cardiac tissues. Neurological Disorders present another challenging domain where gene therapy could bring breakthroughs in treating complex conditions such as Alzheimer’s disease, Parkinson's disease, and spinal muscular atrophy. The therapeutic potential in these areas is underscored by ongoing Research and Development initiatives, fostered by supportive governmental policies in South Korea that encourage biomedical innovation and streamline regulatory processes for introducing new therapies into the market. This confluence of demand, innovation, and supportive infrastructure positions the South Korea Gene Therapy Market as a growing force in the healthcare industry, with substantial investment opportunities aligned with unmet medical needs across these critical therapeutic areas. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Gene Therapy Market Technology Insights** The Technology segment of the South Korea Gene Therapy Market plays a crucial role in shaping the landscape of modern therapeutics. With significant focus on advanced modalities such as Viral Vectors, CRISPR, Gene Editing, RNA Therapy, and Non-Viral Methods, this segment has become a cornerstone for innovation and development in gene therapy. Viral Vectors are widely recognized for their effectiveness in delivering therapeutic genes into target cells, making them essential for successful treatment outcomes.  Similarly, CRISPR technology has revolutionized the field by providing precise gene editing capabilities, enabling researchers to manipulate genetic material with unprecedented accuracy.The Gene Editing technology category is rapidly evolving, supporting the development of new therapies for genetic disorders. RNA Therapy has gained traction due to its potential in treating a wide range of diseases by modulating gene expression, while Non-Viral Methods are increasingly popular for their safety and efficiency, allowing for innovative approaches to gene delivery.  Collectively, these technologies drive the South Korea Gene Therapy Market forward, addressing various unmet medical needs and paving the way for future advancements in personalized medicine and therapeutic interventions.As the market continues to grow, investments in Research and Development are vital to overcoming challenges and harnessing the full potential of these transformative technologies. **Gene Therapy Market Application Insights** The South Korea Gene Therapy Market has witnessed significant growth in its Application segment, encompassing Research, Clinical, and Commercial areas. The nation has positioned itself as a leader in biotechnology, supported by strong government initiatives such as the "K-Bio" strategy, which promotes innovative research and development in gene therapy. The Research aspect is crucial as it drives the discovery and development of novel therapeutic techniques, addressing genetic disorders and advancing personalized medicine.  The Clinical application is imperative for translating innovative research findings into practical treatments, with numerous ongoing clinical trials focusing on a wide range of diseases, highlighting its importance in healthcare delivery.In the Commercial domain, gene therapies are becoming increasingly accessible to patients, opened by various partnerships and collaborations between biopharmaceutical companies and research institutions.  This dynamic encourages more investments, accelerates market growth, and enhances patient outcomes, making the Application segment a pivotal factor in the overall landscape of the South Korea Gene Therapy Market. As such, continuous innovations and collaborations are likely to sustain the momentum of growth in this segment. **Gene Therapy Market Route of Administration Insights** The South Korea Gene Therapy Market exhibits a diverse range of delivery mechanisms under the Route of Administration segment, which significantly influences treatment effectiveness and patient compliance. Intravenous administration is crucial due to its rapid systemic distribution, making it an essential method for treating various genetic disorders. Intramuscular routes receive attention for their ease of administration and potential for self-administration, which broadens accessibility for patients. Intradermal methods show promise for localized treatments, particularly for skin-related genetic issues, while intrathecal delivery is critical for targeting central nervous system disorders, ensuring that therapeutic agents effectively reach specific neural tissues. Oral administration's versatility and potential for patient comfort make it an appealing choice, possibly enhancing adherence to treatment protocols. The combination of these various routes highlights the market's adaptability and responsiveness to patient needs within South Korea, driven by advances in technology and evolving healthcare policies that aim to improve patient outcomes and drive market growth. As the healthcare landscape continues to adapt, these routes play a significant role in shaping the development and delivery of innovative gene therapies, reflecting both market trends and unique regional healthcare dynamics. **South Korea Gene Therapy Market Key Players and Competitive Insights** The South Korea Gene Therapy Market is witnessing a dynamic and competitive landscape characterized by rapid advancements in technology, increasing investments in research and development, and a growing focus on personalized medicine. The market reflects a strong emphasis on innovative therapies aimed at treating genetic disorders, cancers, and rare diseases. Several players are leveraging breakthrough technologies, including CRISPR and AAV vectors, to develop novel gene therapies that promise improved outcomes. The regulatory environment in South Korea is also evolving to support the development and commercialization of gene therapies, which is enhancing the competitive atmosphere.  As a result, companies are now focusing on collaboration, partnerships, and strategic alliances to capitalize on emerging opportunities and navigate challenges inherent in the development of gene therapeutics.Amgen has established a strong presence in the South Korea Gene Therapy Market, driven by its innovative research portfolio focusing on advanced therapeutic solutions. The company has emphasized the integration of biotechnology with gene therapy principles that align with the region's healthcare needs. Amgen’s strengths lie in its robust pipeline of treatment candidates targeting various genetic conditions and diseases, along with its commitment to precision medicine. The company has invested significantly in local collaborations that enhance its operational capabilities and market reach, demonstrating its dedication to the South Korean market.  This emphasis on partnerships not only accelerates the development of potential therapies but also enhances patient accessibility to innovative treatments, thereby strengthening Amgen's brand and market position in South Korea.Genethon is a prominent player within the South Korea Gene Therapy Market, recognized for its contributions to the development of therapies aimed at rare genetic disorders. The company focuses on advanced gene therapy techniques, leveraging its expertise to create effective treatment options. Genethon has established strategic alliances with local academic and healthcare institutions, facilitating knowledge exchange and research collaboration that is crucial for accelerating therapy development.  The company is known for its leading products and research initiatives, making significant strides in the commercialization of gene therapies targeted for various conditions prevalent within South Korea. Genethon's commitment to innovation is further highlighted through key mergers and acquisitions that bolster its R&D capabilities, enhancing its ability to deliver cutting-edge therapies that meet the unique healthcare needs of the South Korean population. **Key Companies in the South Korea Gene Therapy Market Include** **South Korea Gene Therapy Market Industry Developments** The South Korea Gene Therapy Market has witnessed significant developments recently, with Amgen and GSK focusing on expanding their presence through enhanced research initiatives. In October 2023, Samsung Biologics announced a substantial investment aimed at increasing its manufacturing capabilities for gene therapy products, reflecting the growing demand in the region. There has been a notable rise in the market valuation of companies such as LG Chem and BristolMyers Squibb, driven by their advancements in gene editing techniques and successful clinical trials. In terms of mergers and acquisitions, Genzyme acquired notable gene therapy assets from Sangamo Therapeutics in September 2023, further consolidating its position in the market.  Recent statistics indicate that South Korea's government is prioritizing biopharmaceuticals as a key growth sector, pledging additional support for Research and Development projects. Over the last two to three years, the gene therapy landscape has gained heightened attention, with regulatory approvals accelerating for therapies addressing rare diseases. The increased collaboration among major players like Roche and Novartis has also stimulated innovation, promoting South Korea as a vital hub for gene therapy research and development in the Asia-Pacific region. **South Korea Gene Therapy Market Segmentation Insights** **Gene Therapy Market Therapeutic Area****Outlook** **Gene Therapy Market Technology****Outlook** **Gene Therapy Market Application****Outlook** **Gene Therapy Market Route of Administration****Outlook** ## Market Drivers ### Regulatory Framework Enhancements The regulatory landscape in South Korea is evolving to support the gene therapy market. The Ministry of Food and Drug Safety (MFDS) has implemented streamlined approval processes for gene therapies, which may expedite the time to market for innovative treatments. This regulatory support is crucial, as it encourages investment in research and development, potentially leading to a surge in new therapies. In 2024, the MFDS approved several gene therapies, reflecting a growing acceptance of these treatments. The favorable regulatory environment is likely to attract both domestic and international companies, fostering a competitive market. As a result, the gene therapy market could experience accelerated growth, with projections indicating a compound annual growth rate (CAGR) of over 15% through 2028. ### Rising Incidence of Rare Diseases The incidence of rare genetic diseases is increasing in South Korea, which is driving the demand for gene therapies. As the population becomes more aware of these conditions, there is a growing recognition of the need for effective treatments. The gene therapy market is particularly well-positioned to address these unmet medical needs, as many rare diseases are caused by genetic mutations that can potentially be corrected through gene therapy. In 2025, it is estimated that approximately 1 in 10,000 individuals are affected by rare genetic disorders, highlighting the urgency for innovative solutions. This rising incidence is likely to propel the gene therapy market forward, as stakeholders seek to develop targeted therapies for these conditions. ### Growing Patient Awareness and Demand Patient awareness regarding genetic disorders and available treatments is on the rise in South Korea, which is positively influencing the gene therapy market. Educational campaigns and advocacy groups are playing a pivotal role in informing the public about genetic conditions and the potential of gene therapies. This heightened awareness is likely to lead to increased demand for innovative treatments, as patients seek out options that address their specific genetic conditions. In 2025, surveys indicate that over 60% of patients are actively seeking information about gene therapies, reflecting a shift in patient attitudes. Consequently, the gene therapy market may experience growth as healthcare providers respond to this demand by offering more gene-based treatment options. ### Increased Investment in Biotechnology Investment in biotechnology is witnessing a notable rise in South Korea, significantly impacting the gene therapy market. Venture capital funding for biotech firms has surged, with estimates suggesting an increase of approximately 30% in 2025 compared to previous years. This influx of capital is facilitating the development of innovative gene therapies, as companies are able to allocate resources towards research and clinical trials. Furthermore, government initiatives aimed at fostering biotech innovation are likely to enhance the attractiveness of the sector. As a result, the gene therapy market is poised for expansion, with a projected market value reaching $1 billion by 2027, driven by increased investment and innovation. ### Collaborations Between Academia and Industry Collaborative efforts between academic institutions and biotech companies are becoming increasingly prevalent in South Korea, significantly impacting the gene therapy market. These partnerships facilitate the exchange of knowledge and resources, leading to accelerated research and development of novel therapies. Universities are often at the forefront of genetic research, and their collaboration with industry players can enhance the translation of scientific discoveries into clinical applications. In 2025, several high-profile collaborations have been announced, indicating a trend towards synergistic efforts in the gene therapy space. This collaborative environment is likely to foster innovation, potentially resulting in a more robust pipeline of gene therapies entering the market. ## Future Outlook The [Gene Therapy Market](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) is projected to grow at a 19.04% CAGR from 2025 to 2035, driven by advancements in technology, regulatory support, and increasing disease prevalence. **New opportunities:** - Development of personalized gene therapies for rare diseases - Expansion of telehealth services for remote patient monitoring - Investment in gene editing technologies to enhance treatment efficacy By 2035, the gene therapy market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Vector Type: Viral Vector (Largest) vs. Non-Viral Vector (Fastest-Growing) In the South Korea gene therapy market, the distribution of market share favors viral vectors, which dominate due to their proven efficacy in delivering therapeutic genes. The continued investment in research and development, coupled with successful case studies, has solidified viral vectors' position as the go-to choice for many gene therapies. Conversely, non-viral vectors are gaining traction, thanks to lower immunogenicity and enhanced safety profiles, but they currently hold a smaller portion of the market share. The growth trends in the South Korea gene therapy market are being driven primarily by advancements in both viral and non-viral vector technologies. Notably, non-viral vectors are emerging as a vital alternative due to their innovative delivery mechanisms that reduce the risk of adverse reactions. The overall market is experiencing a surge in demand as more research institutions and biopharmaceutical companies explore diverse gene therapy options, further propelling the growth of these segment values. Technology: Viral Vector (Dominant) vs. Non-Viral Vector (Emerging) Viral vectors are extensively utilized in the South Korea gene therapy market, characterized by their effectiveness in gene delivery and ability to transduce both dividing and non-dividing cells. Their dominance is largely attributed to established manufacturing processes and track records of success in clinical applications. Conversely, non-viral vectors are recognized as an emerging technology and appeal due to their reduced immunogenic response and enhanced safety. These vectors encompass various approaches, including liposomes and plasmid DNA, which are being increasingly adopted owing to their potential for more controlled gene expression and scalability. As a result, both segment values are pivotal in shaping the landscape of gene therapies, with viral vectors currently leading while non-viral vectors steadily gain ground. ### By Gene Type: Antigen (Largest) vs. Cytokine (Fastest-Growing) In the South Korea gene therapy market, the distribution of market share among various gene types reveals that Antigen is the largest segment, capturing a significant portion of the overall market. This is followed by Cytokine, which, while not the largest, is recognized for its rapid growth and increasing adoption in therapeutic applications. Other segments, such as Tumor Suppressor, Suicide, and Deficiency genes, also hold noteworthy positions, contributing to the diverse landscape of gene therapies available in the region. The growth trends within the South Korea gene therapy market are driven by advancements in biotechnological research and increasing investments in developing innovative therapies. Specifically, the heightened focus on personalized medicine and the expanding prevalence of genetic disorders are pivotal factors fueling growth. Key players in the market are continually enhancing their R&D capabilities and exploring novel gene types, which is expected to further accelerate the expansion of the market in the coming years. Gene Type: Antigen (Dominant) vs. Cytokine (Emerging) The Antigen segment stands out as the dominant force in the South Korea gene therapy market due to its established applications in immunotherapy and vaccine development. Antigens have been pivotal in creating targeted therapies that stimulate the immune system, thus gaining wide acceptance among healthcare providers and patients. Conversely, the Cytokine segment is emerging rapidly, showcasing innovative approaches to modulating immune responses. Cytokines have garnered attention for their potential in treating chronic inflammatory conditions and cancers, positioning them as a crucial area for future expansion. The synergy between these segments illustrates a dynamic interplay within the market, as both continue to evolve and respond to healthcare needs. ### By Application: Oncological Disorders (Largest) vs. Rare Diseases (Fastest-Growing) The South Korea gene therapy market showcases a diverse application landscape, with oncological disorders leading the charge in market share. This segment is recognized for its substantial presence, driven by increasing incidences of cancer and advancements in therapeutic technologies. Following closely are rare diseases, rapidly gaining traction as research focuses on improving treatment options for these previously neglected conditions, contributing to their swift growth in the market. The growth trends in the South Korea gene therapy market are significantly influenced by ongoing research and substantial investments in biotechnology. Factors such as an aging population, rising healthcare expenditures, and enhanced regulatory support for innovative therapies are propelling the market forward. Additionally, the surge in awareness about targeted therapies for rare diseases is fostering rapid developments, positioning this segment as an emerging powerhouse within the market landscape. Oncological Disorders (Dominant) vs. Neurological Disorders (Emerging) Oncological disorders dominate the application segment of the South Korea gene therapy market, largely due to the increasing demand for effective cancer treatments and continuous breakthroughs in gene-based therapies. This segment captures the attention of researchers and investors alike, as novel approaches like CAR-T therapies offer significant promise for oncology treatment. Conversely, neurological disorders represent an emerging market segment, experiencing accelerated development driven by rising incidents of conditions like Alzheimer’s and Parkinson’s disease. This surge is fueled by an urgent need for innovative solutions, and as a result, new therapies targeting neurological conditions are evolving rapidly, supported by collaborations between pharmaceutical companies and academic institutions. ### By Delivery Method: In Vivo Gene Therapy (Largest) vs. Ex Vivo Gene Therapy (Fastest-Growing) The South Korea gene therapy market is witnessing a significant division in its delivery methods, with In Vivo gene therapy holding the largest market share. This approach allows for the direct introduction of therapeutic agents into the patient's body, which appeals to healthcare providers seeking efficient solutions for various genetic disorders. Ex Vivo gene therapy, while currently smaller in market share, is gaining traction thanks to advancements in technology and targeted applications that enhance patient outcomes. Growth trends in this segment are driven by increasing prevalence of genetic disorders and advancements in biotechnology. The demand for In Vivo gene therapy is primarily propelled by its ability to offer immediate intervention, whereas Ex Vivo gene therapy is emerging rapidly due to its promise of tailoring treatments to individual genetic profiles. Both methods are expected to expand in capabilities and applications, reflecting the dynamic nature of the market. Delivery Method: In Vivo Gene Therapy (Dominant) vs. Ex Vivo Gene Therapy (Emerging) In Vivo gene therapy is characterized by its ability to directly deliver therapeutic genes into specific tissues or cells, offering a seamless and less invasive treatment option. This method dominates the South Korea gene therapy market due to its established protocols and extensive research backing its efficacy. On the other hand, Ex Vivo gene therapy, while emerging, focuses on manipulating cells outside the body before reintroducing them, thus allowing for precision treatment tailored to individual patient needs. This personalized approach enhances the potential for successful outcomes and is gaining popularity among practitioners and patients alike. As innovations drive both sectors, their unique benefits will cater to a broader spectrum of genetic disorders. ## Competitive Benchmarking The gene therapy market in South Korea is characterized by a dynamic competitive landscape, driven by rapid advancements in biotechnology and increasing investments in research and development. Key players are focusing on innovation and strategic partnerships to enhance their market presence. Companies such as Novartis (CH), Gilead Sciences (US), and Spark Therapeutics (US) are at the forefront, leveraging their expertise in gene editing and delivery systems. Their operational focus appears to be on developing cutting-edge therapies that address unmet medical needs, thereby shaping a competitive environment that emphasizes technological advancement and patient-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. The market structure is moderately fragmented, with several players vying for dominance. This fragmentation allows for a diverse range of therapies and approaches, but it also intensifies competition among key players. The collective influence of these companies is significant, as they drive innovation and set industry standards through their strategic initiatives. In October 2025, Gilead Sciences (US) announced a collaboration with a South Korean biotech firm to develop a novel gene therapy targeting rare genetic disorders. This partnership is strategically important as it not only enhances Gilead's portfolio but also allows for localized expertise in navigating regulatory pathways in South Korea. Such collaborations are likely to accelerate the development timeline and improve market access for innovative therapies. In September 2025, Novartis (CH) launched a new gene therapy aimed at treating a specific type of inherited retinal disease. This launch underscores Novartis's commitment to expanding its gene therapy offerings and reflects a broader trend of companies investing in specialized treatments. The strategic importance of this move lies in its potential to capture a niche market segment, thereby enhancing Novartis's competitive positioning in the region. In August 2025, Spark Therapeutics (US) secured a partnership with a leading South Korean research institution to advance its gene therapy research. This collaboration is indicative of a growing trend where companies seek to leverage local expertise and resources to enhance their research capabilities. The strategic implications are profound, as such partnerships can lead to accelerated innovation and improved therapeutic outcomes. As of November 2025, current competitive trends in the gene therapy market include a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence in research and development processes. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these areas will be better positioned to thrive in an increasingly complex market. ## Recent News & Developments The South Korea Gene Therapy Market has witnessed significant developments recently, with Amgen and GSK focusing on expanding their presence through enhanced research initiatives. In October 2023, Samsung Biologics announced a substantial investment aimed at increasing its manufacturing capabilities for gene therapy products, reflecting the growing demand in the region. There has been a notable rise in the market valuation of companies such as LG Chem and BristolMyers Squibb, driven by their advancements in gene editing techniques and successful clinical trials. In terms of mergers and acquisitions, Genzyme acquired notable gene therapy assets from Sangamo Therapeutics in September 2023, further consolidating its position in the market.  Recent statistics indicate that South Korea's government is prioritizing biopharmaceuticals as a key growth sector, pledging additional support for Research and Development projects. Over the last two to three years, the gene therapy landscape has gained heightened attention, with regulatory approvals accelerating for therapies addressing rare diseases. The increased collaboration among major players like Roche and Novartis has also stimulated innovation, promoting South Korea as a vital hub for gene therapy research and development in the Asia-Pacific region. ## Report Scope | South Korea MARKET SIZE 2024 | 122.4(USD Million) | | --- | --- | | South Korea MARKET SIZE 2025 | 145.7(USD Million) | | South Korea MARKET SIZE 2035 | 832.7(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 19.04% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Gilead Sciences (US), Spark Therapeutics (US), Bluebird Bio (US), Bristol-Myers Squibb (US), Regeneron Pharmaceuticals (US), Sangamo Therapeutics (US), Amgen (US), Roche (CH) | | Segments Covered | Vector Type, Gene Type, Application, Delivery Method | | Key Market Opportunities In South Korea | Advancements in gene editing technologies enhance treatment options in the gene therapy market. | | Key Market Dynamics In South Korea | Growing investment in Research and Development drives innovation in the gene therapy market, enhancing treatment options. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What was the market valuation of the gene therapy market in 2024?** A: The market valuation was $122.4 Million in 2024. **Q: What is the projected market valuation for the gene therapy market in 2035?** A: The projected market valuation for 2035 is $832.7 Million. **Q: What is the expected CAGR for the gene therapy market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during 2025 - 2035 is 19.04%. **Q: Which companies are considered key players in the gene therapy market?** A: Key players include Novartis, Gilead Sciences, Spark Therapeutics, Bluebird Bio, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Sangamo Therapeutics, Amgen, and Roche. **Q: What are the two main types of vectors used in gene therapy, and what were their valuations in 2024?** A: In 2024, Viral Vector was valued at $73.44 Million, while Non-Viral Vector was valued at $48.96 Million. **Q: What types of genes are being targeted in the gene therapy market, and what were their valuations in 2024?** A: In 2024, Antigen was valued at $24.6 Million, Cytokine at $18.4 Million, and Tumor Suppressor at $20.0 Million, among others. **Q: What applications are driving the gene therapy market, and what were their valuations in 2024?** A: In 2024, Rare Diseases had a valuation of $30.7 Million, while Oncological Disorders were valued at $24.6 Million. **Q: What delivery methods are utilized in gene therapy, and what were their valuations in 2024?** A: In 2024, In Vivo Gene Therapy was valued at $73.44 Million, and Ex Vivo Gene Therapy was valued at $48.96 Million. **Q: How does the gene therapy market in South Korea compare to global trends?** A: While specific global comparisons are not provided, the South Korea market is expected to grow significantly, indicating a robust local industry. **Q: What factors are contributing to the growth of the gene therapy market in South Korea?** A: Factors include advancements in technology, increasing investment from key players, and a growing focus on rare and oncological diseases. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-gene-therapy-market-53259*